Ponsegromab

Ponsegromab
Monoclonal antibody
Type	?
Target	GDF-15
Clinical data
Other names	PF-06946860
Legal status
Legal status	Investigational;
Identifiers
CAS Number	2368950-15-4;
UNII	GXA6PF0254;

Ponsegromab (PF-06946860) is a monoclonal antibody that works as a GDF-15 inhibitor. It is developed by Pfizer for cancer cachexia.^[1]^[2]^[3]^[4]^[5]

References[edit]

^ Nishie, Kenichi; Nishie, Tomomi; Sato, Seiichi; Hanaoka, Masayuki (September 2023). "Update on the treatment of cancer cachexia". Drug Discovery Today. 28 (9): 103689. doi:10.1016/j.drudis.2023.103689. PMID 37385369. S2CID 259294809.
^ Roeland, E.J.; Yennu, S.; Del Fabbro, E.; Buckeridge, C.; Thayer, K.M.; Collins, S.M.; Lubaczewski, S.L.; Wang, E.Q.; Calle, R.A. (September 2021). "1696TiP Phase Ib study to assess the effect of PF-06946860 on appetite following subcutaneous administration in patients with anorexia and advanced cancer". Annals of Oncology. 32: S1185. doi:10.1016/j.annonc.2021.08.1668.
^ Crawford, Jeffrey; Lubaczewski, Shannon L; Tarachandani, Anil; Harrington, Magdalena A; Weng, Yan; Qiu, Ruolun; Collins, Susie M; Rossulek, Michelle I; Revkin, James H (1 June 2023). "Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia". Journal of Clinical Oncology. 41 (16_suppl): TPS12147. doi:10.1200/JCO.2023.41.16_suppl.TPS12147.
^ Crawford, Jeffrey; Calle, Roberto A.; Collins, Susie M.; Weng, Yan; Lubaczewski, Shannon L.; Buckeridge, Clare; Wang, Ellen Q.; Harrington, Magdalena A.; Tarachandani, Anil; Rossulek, Michelle I.; Revkin, James H. (14 April 2023). "Abstract CT108: First-in-patient study of the GDF-15 inhibitor ponsegromab in patients with cancer and cachexia: Safety, tolerability, and exploratory measures of efficacy". Cancer Research. 83 (8_Supplement): CT108. doi:10.1158/1538-7445.AM2023-CT108. S2CID 258165004.
^ Talbert, Erin E.; Guttridge, Denis C. (May 2022). "Emerging signaling mediators in the anorexia–cachexia syndrome of cancer". Trends in Cancer. 8 (5): 397–403. doi:10.1016/j.trecan.2022.01.004. PMC 9035074. PMID 35190301.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Nishie, Kenichi; Nishie, Tomomi; Sato, Seiichi; Hanaoka, Masayuki (September 2023). "Update on the treatment of cancer cachexia". Drug Discovery Today. 28 (9): 103689. doi:10.1016/j.drudis.2023.103689. PMID 37385369. S2CID 259294809.

[2] Roeland, E.J.; Yennu, S.; Del Fabbro, E.; Buckeridge, C.; Thayer, K.M.; Collins, S.M.; Lubaczewski, S.L.; Wang, E.Q.; Calle, R.A. (September 2021). "1696TiP Phase Ib study to assess the effect of PF-06946860 on appetite following subcutaneous administration in patients with anorexia and advanced cancer". Annals of Oncology. 32: S1185. doi:10.1016/j.annonc.2021.08.1668.

[3] Crawford, Jeffrey; Lubaczewski, Shannon L; Tarachandani, Anil; Harrington, Magdalena A; Weng, Yan; Qiu, Ruolun; Collins, Susie M; Rossulek, Michelle I; Revkin, James H (1 June 2023). "Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia". Journal of Clinical Oncology. 41 (16_suppl): TPS12147. doi:10.1200/JCO.2023.41.16_suppl.TPS12147.

[4] Crawford, Jeffrey; Calle, Roberto A.; Collins, Susie M.; Weng, Yan; Lubaczewski, Shannon L.; Buckeridge, Clare; Wang, Ellen Q.; Harrington, Magdalena A.; Tarachandani, Anil; Rossulek, Michelle I.; Revkin, James H. (14 April 2023). "Abstract CT108: First-in-patient study of the GDF-15 inhibitor ponsegromab in patients with cancer and cachexia: Safety, tolerability, and exploratory measures of efficacy". Cancer Research. 83 (8_Supplement): CT108. doi:10.1158/1538-7445.AM2023-CT108. S2CID 258165004.

[5] Talbert, Erin E.; Guttridge, Denis C. (May 2022). "Emerging signaling mediators in the anorexia–cachexia syndrome of cancer". Trends in Cancer. 8 (5): 397–403. doi:10.1016/j.trecan.2022.01.004. PMC 9035074. PMID 35190301.

[1]

[2]

[3]

[4]

[5]